Premium
Kolaviron quenches ischaemic‐reperfusion injury (IRI) in isolated rat heart via activation of Akt/PKB and suppression of p38MAPK/PARP/Caspase 3 signalling pathways
Author(s) -
Oyagbemi Ademola Adetokunbo,
Bester Dirk,
Esterhuyse Johan,
Farombi Olatunde
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.1069.3
Subject(s) - protein kinase b , pharmacology , malondialdehyde , cardioprotection , superoxide dismutase , chemistry , reactive oxygen species , glutathione peroxidase , reperfusion injury , western blot , medicine , ischemia , oxidative stress , endocrinology , apoptosis , biochemistry , gene
The study was designed to investigate the ameliorative effect of Kolaviron (KV) on ischaemic‐reperfusion injury in experimental rat models. Twenty male Wistar rats were randomly divided into 2 groups: Group one received corn oil as a vehicle and rats in group two were orally administered KV at 200 mg/kg for four weeks. After four weeks of KV pre‐treatment, hearts were excised and mounted on the Working heart perfusion system. Western blot analysis was carried out on frozen heart samples. From this study, there was a significant (p<0.05) reduction in the activity of catalase, superoxide dismutase and glutathione peroxidase with concomitant reduction in oxygen radical absorbance capacity (ORAC) in ischaemic rat heart of animals that received corn oil without KV pre‐treatment. Similarly, pre‐treatment of rats with KV led to a significant (p<0.05) decline in intracellular reactive oxygen species (ROS) and malondialdehyde. Western blots analyses revealed that KV significantly increased the expressions of total Akt/PKB, phosphorylated Akt/PKB at serine 473 and also caused a significant reduction in p38 MAPK, Caspase 3, and cleaved PARP. Combining all, we propose that KV offered notable cardioprotection via quenching of ROS and up‐regulation of pro‐survival sinalling pathways. KV may therefore offer a novel therepeutic window for cardiovascular and other heart related conditions.